Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Shire Behind Him, Jonas Starts New Chapter At SAGE

This article was originally published in The Pink Sheet Daily

Executive Summary

The upbeat ex-Shire exec has moved on from his tumultuous break-up with the specialty pharma and is on day three in his new role as CEO of CNS start-up SAGE Therapeutics. He will focus on bringing CNS products forward for orphan indications.

You may also be interested in...



Financings of the Fortnight Wants To Spin You Right 'Round, And Out

Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.

Shire Sheds Dermagraft; Exits Regenerative Medicine

The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.

Eyeing Epilepsy Franchise, SAGE Therapeutics Raises $20M

ARCH Venture Partners joined original investor Third Rock Ventures in backing the Cambridge, Mass., start-up with $20 million in Series B money. SAGE is concentrating its efforts on several compounds, including one to treat a type of epileptic seizure, which could represent the beginning of a larger epilepsy franchise.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel